Physician profile
Joseph C Drumm
NPI 1619262680
$12,646.15
in general payments reported to CMS, 2019-2025
14 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,557 · 2021: $357 · 2022: $148 · 2023: $14.11 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,338.06 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $332.55 | 2021-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.97 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $180.21 | 2019-2025 | Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $143.93 | 2020-2025 | Abilify Asimtufii, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $102.42 | 2020 | |
| Lundbeck LLC | $86.16 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $48.72 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $41.39 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $29.19 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.84 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $24.11 | 2020 | |
| Abbvie INC. | $16.15 | 2022 | |
| Alkermes, INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Drumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.